231 related articles for article (PubMed ID: 10632373)
1. MST-16, a novel bis-dioxopiperazine anticancer agent, ameliorates doxorubicin-induced acute toxicity while maintaining antitumor efficacy.
Yoshida M; Maehara Y; Sugimachi K
Clin Cancer Res; 1999 Dec; 5(12):4295-300. PubMed ID: 10632373
[TBL] [Abstract][Full Text] [Related]
2. MST-16, a novel derivative of bis(2,6-dioxopiperazine), synergistically enhances the antitumor effects of anthracyclines.
Inutsuka S; Baba H; Maehara Y; Sugimachi K
Cancer Chemother Pharmacol; 1998; 42(3):194-200. PubMed ID: 9685054
[TBL] [Abstract][Full Text] [Related]
3. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
[TBL] [Abstract][Full Text] [Related]
4. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
Wong HL; Rauth AM; Bendayan R; Wu XY
Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
[TBL] [Abstract][Full Text] [Related]
5. Anti-proliferative effects, cell cycle G2/M phase arrest and blocking of chromosome segregation by probimane and MST-16 in human tumor cell lines.
Lu DY; Huang M; Xu CH; Yang WY; Hu CX; Lin LP; Tong LJ; Li MH; Lu W; Zhang XW; Ding J
BMC Pharmacol; 2005 Jun; 5():11. PubMed ID: 15963241
[TBL] [Abstract][Full Text] [Related]
6. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
[TBL] [Abstract][Full Text] [Related]
7. Schedule-dependent interaction between Doxorubicin and mTHPC-mediated photodynamic therapy in murine hepatoma in vitro and in vivo.
Kirveliene V; Grazeliene G; Dabkeviciene D; Micke I; Kirvelis D; Juodka B; Didziapetriene J
Cancer Chemother Pharmacol; 2006 Jan; 57(1):65-72. PubMed ID: 16001168
[TBL] [Abstract][Full Text] [Related]
8. Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin.
Miller RA; Woodburn KW; Fan Q; Lee I; Miles D; Duran G; Sikic B; Magda D
Clin Cancer Res; 2001 Oct; 7(10):3215-21. PubMed ID: 11595717
[TBL] [Abstract][Full Text] [Related]
9. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Br J Cancer; 2001 Feb; 84(4):550-7. PubMed ID: 11207053
[TBL] [Abstract][Full Text] [Related]
10. Preclinical models of cardiac protection and testing for effects of dexrazoxane on doxorubicin antitumor effects.
Imondi AR
Semin Oncol; 1998 Aug; 25(4 Suppl 10):22-30. PubMed ID: 9768820
[TBL] [Abstract][Full Text] [Related]
11. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.
Trail PA; Willner D; Knipe J; Henderson AJ; Lasch SJ; Zoeckler ME; TrailSmith MD; Doyle TW; King HD; Casazza AM; Braslawsky GR; Brown J; Hofstead SJ; Greenfield RS; Firestone RA; Mosure K; Kadow KF; Yang MB; Hellström KE; Hellström I
Cancer Res; 1997 Jan; 57(1):100-5. PubMed ID: 8988048
[TBL] [Abstract][Full Text] [Related]
12. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
van Acker SA; Boven E; Kuiper K; van den Berg DJ; Grimbergen JA; Kramer K; Bast A; van der Vijgh WJ
Clin Cancer Res; 1997 Oct; 3(10):1747-54. PubMed ID: 9815559
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effect of probimane on anticancer cytotoxicity of doxorubicin in vitro.
Zhang Y; Ye QX; Liu J; Zhang ZY; Zhang TM
Zhongguo Yao Li Xue Bao; 1994 Jan; 15(1):56-9. PubMed ID: 8010087
[TBL] [Abstract][Full Text] [Related]
14. Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors.
van Lummel M; van Blitterswijk WJ; Vink SR; Veldman RJ; van der Valk MA; Schipper D; Dicheva BM; Eggermont AM; ten Hagen TL; Verheij M; Koning GA
FASEB J; 2011 Jan; 25(1):280-9. PubMed ID: 20876209
[TBL] [Abstract][Full Text] [Related]
15. [Synergism of sobuzoxane in combination with doxorubicin against leukemia P388 in mice].
Dai ZQ; Xu JY; Yuan XJ; Cai JC
Zhongguo Yao Li Xue Bao; 1996 Jan; 17(1):69-71. PubMed ID: 8737460
[TBL] [Abstract][Full Text] [Related]
16. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.
Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR
Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390
[TBL] [Abstract][Full Text] [Related]
17. Combination efficacy of doxorubicin and adenoviral methioninase gene therapy with prodrug selenomethionine.
Gupta A; Miki K; Xu M; Yamamoto N; Moossa AR; Hoffman RM
Anticancer Res; 2003; 23(2B):1181-8. PubMed ID: 12820369
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo antitumor effects of doxorubicin loaded with bacterial magnetosomes (DBMs) on H22 cells: the magnetic bio-nanoparticles as drug carriers.
Sun JB; Duan JH; Dai SL; Ren J; Zhang YD; Tian JS; Li Y
Cancer Lett; 2007 Dec; 258(1):109-17. PubMed ID: 17920762
[TBL] [Abstract][Full Text] [Related]
19. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
Bruynzeel AM; Mul PP; Berkhof J; Bast A; Niessen HW; van der Vijgh WJ
Cancer Chemother Pharmacol; 2006 Nov; 58(5):699-702. PubMed ID: 16565833
[TBL] [Abstract][Full Text] [Related]
20. Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.
Devy L; de Groot FM; Blacher S; Hajitou A; Beusker PH; Scheeren HW; Foidart JM; Noël A
FASEB J; 2004 Mar; 18(3):565-7. PubMed ID: 14734647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
